Published online Dec 28, 2020. doi: 10.3748/wjg.v26.i48.7593
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
Peer-review started: September 29, 2020
First decision: November 8, 2020
Revised: November 14, 2020
Accepted: November 29, 2020
Article in press: November 29, 2020
Published online: December 28, 2020
Processing time: 87 Days and 8.7 Hours
Ulcerative colitis (UC) is a chronic relapsed intestinal disease with an increasing incidence around the world. The pathophysiology of UC remains unclear. However, the role of the interaction between the enteric nervous system and the immune system in the pathogenesis of UC has been the focus of attention and has become a research hotspot. Vasoactive intestinal peptide (VIP) is a kind of endogenous neuropeptide with regulatory activity on intestinal immunity. It has been shown to regulate immune disorders in animal and human experiments and has become an effective anti-inflammatory and immune modulator that affects the innate immune system and adaptive immune system. Regulatory B cells (Bregs) are a new group of B cells that negatively regulate the immunity and have received extensive attention in immune circles. Bregs can regulate immune tolerance by producing interleukin (IL)-10, IL-35, and transforming growth factor-β, suppressing autoimmune diseases or excessive inflammatory responses. The secretion of IL-10 by Bregs induces the development of T helper (Th) 0 and Th2 cells. It also induces Th2 cytokines and inhibits Th1 cytokines, thereby inhibiting Th1 cells and the Th1/Th2 balance. With further clarity on the mechanism of the regulation of IL-10 expression by VIP in Bregs in colitis patients, we believe that Bregs can provide a novel strategy for the clinical treatment of UC. Thus, we aim to review the current literature on this evolving topic.
Core Tip: The pathophysiology of ulcerative colitis remains unclear. Vasoactive intestinal peptide (VIP) is a neuropeptide that has strong regulatory activity on intestinal immunity. With further clarity on the mechanism of the regulation of interleukin-10 expression by VIP in regulatory B cells in colitis patients, we believe that VIP can provide a novel strategy for the clinical treatment of ulcerative colitis.